Clinical Trial

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Completed
View on ClinicalTrials.gov →
Summary
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-10; most recent amendment 2026-03-18.
Status change: Recruiting → Completed 2026-03-18
Trial Details
NCT Number NCT07216651
Lead Sponsor Closed Loop Medicine
Conditions Obesity & Overweight
Enrollment 20 participants
Start Date 2025-09-23
Primary Completion 2026-02-27 (estimated)
Study Completion 2026-03-18 (estimated)
Updated on ClinicalTrials.gov 2026-03-19